107 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
million in Q1 2024; continuing to expand global access with 7 additional launches since January 2024
Phase 1/2 brenetafusp (IMC-F106C; PRAME-A02 … received KIMMTRAK with 0.8% being grade 3 or 4. Ensure immediate access to medications and resuscitative equipment to manage CRS. Ensure patients
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
for the amount of net product revenue in France. Rebates payable to the Economic Committee for Health Products, or CEPS, under early access and commercial … access and commercial programs until this price is agreed. Analysis of further legislative requirements, sales volumes and the expected benefit
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
been received and accepted. If you have not been provided with your meeting access credentials, please ensure you contact Computershare on the morning … of the AGM, but no later than 2 hours before the start of the AGM.
Access to the AGM via meetnow.global/IHCAGM2024 will be available from 2.15 p.m
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
of the registration statement through the SEC’s website, as provided above.
We also maintain a website at www.immunocore.com through which you can access our … for cash all of the Gates Foundation’s shares pursuant to our amended global access commitments agreement with the Gates Foundation.
On May 12, 2022
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
appointment having been received and accepted. If you have not been provided with your meeting access credentials, please ensure you contact … Computershare on the morning of the AGM, but no later than 2 hours before the start of the AGM.
Access to the AGM via meetnow.global/IHCAGM2024 will be available
S-3ASR
kwz9cwtpo1msf49
20 Mar 24
Automatic shelf registration
8:51pm
8-K
EX-99.1
spdz5pnw2k14jp2y cn
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
8-K
EX-99.2
5ryeie08w t8gt8h8vi0
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
EX-10.12
u58eny6ll2y
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
dtyznuw8yr2 zvkza
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
k2gp2v2
28 Feb 24
Annual report
7:33am
10-K
4k3ok u7wcl9y
28 Feb 24
Annual report
7:33am
8-K
EX-99.2
91ngosvjic4hr12tcq
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.1
jb2w1wmtid4czefe
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.2
uq63z5ua3 57lr
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
dglslv
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
u62t2ul ba
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
s6tmeejnajiqecu
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
c143am1uhdjx
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
7slcb 5cgqc
10 Aug 23
Current report (foreign)
8:28am